As in the past, we choose not to include regulatory-related milestones in financial guidance. These are typical and so far we have performed quite well in all of these audits. In addition, we have comprehensive audits by the agency for manufacturing sites and audit selected clinical sites. We believe that we can secure these meetings early in Q2 of fiscal '22, given that the agency still has a further 90 days on the clock after we have discussed and submitted any additional data they require, we do not see a viable path to achieve the PMA in the first half of fiscal '22. We have requested accelerated turnaround times for scheduling such data discussions. The agency has asked us to use their recommended process to discuss the data requirements versus just providing answers to their questions as a better, more reliable way toward the PMA. While additional data requests including more mortality data are not surprising in and of themselves, the process of achieving clarity regarding these additional detail that are needed to support the approval does take some more time. The FDA is requesting additional data in order to value the product and its unique technology. Recently, we had a planed follow-up meeting with the FDA regarding our submission. As per the request from the FDA, this module included mortality follow-up either for patients at both two and three years from the time of treatment. As we discussed on last quarter's call, we submitted our final module of the SurVeil PMA submission to the FDA on June 21.
SRDX DNA RECOGNITION FULL
Tim will provide additional details on our quarterly results including the impact of the CARES Act on our fiscal '21 operating performance as well as our full year fiscal '22 guidance. Our full fiscal year 2021 non-GAAP earnings per share was $0.37. Also we reported GAAP diluted earnings per share of $0.30 for the full year, which benefited from an anticipated $3.6 million reimbursement associated with CARES Act employee retention credit, which favorably impacted our earnings per share by $0.19. Our revenue grew 11% and was driven by solid topline performance in both our Medical Device and In Vitro Diagnostic businesses, which grew 10% and 15% respectively. During the year, we generated $105.1 million of revenue compared to $94.9 million in fiscal '20. Let's begin with a summary of our full year fiscal '21 performance. We've made great strides in delivering on each of these goals. And the third was to optimize cash flow from the In Vitro Diagnostics and Medical Device Coatings offering to support our strategic growth initiatives. The second was to accelerate the advancement of our robust product pipeline through product development, regulatory clearances and clinical evaluations. The first was to continue building traction with SurVeil marching toward PMA approval beginning with our final submission to the FDA. Last fiscal year, we had three primary areas of focus. I'm proud to be a member of such an amazing community that you know at Surmodics. Our success in fiscal '21 is because of their sacrifices. Despite difficult circumstances stemming from the ongoing global COVID-19 pandemic, they persevere tirelessly. Before providing a quick recap of our achievements in fiscal '21, I'd like to thank our incredible team at Surmodics. It has been a solid quarter with significant progress on our strategic objectives. Good morning and thank you for joining us. Maharaj - President and Chief Executive Officer I will now turn the call over to Gary Maharaj. A press release disclosing our quarterly results was issued this morning and is available on our website at. This conference call is being webcast and is accessible through the Investor Relations section of the Surmodics website where the audio recording of the webcast will also be archived for future reference. Today's news release contains reconciliation tables to GAAP results. We'll also refer to non-GAAP measures, because we believe they provide useful information for our investors.